Nanomedicine News

RSS

Experimental Protein Nanoparticle Vaccine Shows Potential to Respond Rapidly to Emerging Viruses

The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus (MERS-CoV) blocked infection in laboratory studies.

From Novavax Inc. 2 May 2014

Biodegradable Nanoparticles Can Carry DNA to Brain Cancer Cells

Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable "nanoparticles" able to carry DNA to brain cancer cells in mice.

30 Apr 2014

Senesco to Present on Cancer-Targeted Gene Therapy and Cell Therapy

Senesco Technologies, Inc. (“Senesco” or the “Company”), announced today that an oral presentation will be delivered on its potential approach to treating hepatocellular carcinoma at the 17th Annual Meeting of the American Society of Gene & Cell Therapy during the session entitled “Cancer-Targeted Gene & Cell Therapy II”.

29 Apr 2014

Novavax Unveiled Evaluation Data of RSV-F Protein Nanoparticle Vaccine in Clinical Trial

Novavax, Inc. today announced positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in women of childbearing age. The randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety of multiple formulations of Novavax' RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate.

From Novavax Inc. 29 Apr 2014

Tekmira Presents New Clinical data for Patisiran for Treating ATTR

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented new clinical data for patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology. The program represents the most clinically advanced application of Tekmira's proprietary LNP delivery technology.

29 Apr 2014

Forecast Report on Global Nanomedicine Market

Research and Markets have announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering.

From Research and Markets 28 Apr 2014

pSivida Selected for the Ophthalmic Companies Showcase at the OIS at Boston, MA

pSivida Corp., a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA.

From EyePoint Pharmaceuticals, Inc. 26 Apr 2014

Researchers Use Gold Nanoparticles to Indicate Presence of Breast Cancer

Purdue University researchers have developed a way to detect and measure cancer levels in a living cell by using tiny gold particles with tails of synthetic DNA.

26 Apr 2014

NIH Scientist is 2014 Recipient of the Ross Prize in Molecular Medicine

John J. O'Shea, M.D., scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has been named the 2014 recipient of the Ross Prize in Molecular Medicine, conferred by the Feinstein Institute's peer-reviewed, open-access journal Molecular Medicine.

26 Apr 2014

MPP Nanotechnology-Based Ophthalmic Products Developer, Kala, Completes $22.5 Million Series B Financing

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing.

25 Apr 2014